Patents Assigned to Assistance Publique-Hopitaux de Paris
  • Publication number: 20210121532
    Abstract: The invention relates to the use of interleukin-2 in treating Sjögren's syndrome in a subject, wherein IL-2 is to be administered at a low dose of less than about 3.5 MIU/day.
    Type: Application
    Filed: February 18, 2019
    Publication date: April 29, 2021
    Applicants: ILTOO PHARMA, ASSISTANCE PUBLIQUE - HÖPITAUX DE PARIS, SORBONNE UNIVERSITÉ
    Inventors: David KLATZMANN, Roberta LORENZON, Michèle ROSENZWAJG, Patrice CACOUB, Arsene MEKINIAN
  • Patent number: 10980404
    Abstract: The invention relates to a method for producing an image numerical classifier, to automatically determine the visualization quality of endoscopy videocapsule images of segments of the digestive tract, comprising a step of acquiring a video in the digestive tract by a videocapsule; a step of extracting images from the video; a so-called “ground truth” step of clinically evaluating the visualization quality of the images based on medical criteria, a step of selecting an initial set of “adequate” visualization images and “inadequate” visualization images, a step of calculating at least one numerical parameter relating to at least one of the medical criteria, a statistical machine learning step to produce the numerical classifier.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: April 20, 2021
    Assignees: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, SORBONNE UNIVERSITÉ, ÉCOLE NATIONALE SUPÉRIEURE DE L'ÉLECTRONIQUE ET DE SES APPLICATIONS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CY CERGY PARIS UNIVERSITÉ
    Inventors: Xavier Dray, Aymeric Histace
  • Patent number: 10981021
    Abstract: The present invention relates to a method for transiently disrupting a region of the blood-brain barrier (BBB) of a human using ultrasounds in the presence of an ultrasound contrast agent, and uses thereof. The method comprises the application of at least one ultrasound (US) beam with a pressure level higher than 1 MPa and a resonance frequency ranging from 0.5 to 1.5 MHz.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: April 20, 2021
    Assignees: Carthera, Assistance Publique Hopitaux de Paris, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Alexandre Carpentier, Michael Canney, Alexandre Vignot
  • Publication number: 20210106415
    Abstract: Device for inspecting the stability of a dental implant (1) in a bone (2), the implant having a free end (1a) and an end (1b) buried in the bone (2). The device comprises an ultrasonic transducer (12) for emitting and collecting an ultrasonic wave reflected from a contact interface (4) between the implant (1) and the bone (2), and providing a measurement signal representing the reflected ultrasonic wave. The device also comprises a processing unit for computing, based on the measurement signal, an indicator (IN) whose value makes it possible to evaluate the integration of the implant (1) into the bone (2). The indicator (IN) corresponds to the average energy of the measurement signal over a time interval (t1-t2) starting at a first time (t1) and ending at a second time (t2). The first time (t1) is between 20 and 80 ?s after the start of the emission of the ultrasonic wave.
    Type: Application
    Filed: April 16, 2019
    Publication date: April 15, 2021
    Applicants: Centre National de la Recherche Scientifique, UNIVERSITE PARIS XII - VAL DE MARNE, L'ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Guillaume Haiat, Romain Vayron
  • Publication number: 20210093247
    Abstract: A computer-implemented method for detecting pathological brain activity patterns from a scalp electroencephalographic signal, the method including the steps of obtaining (A) an electroencephalographic signal as a function of multiple channels and time; identifying (C), for each channel, the zero-crossings of the electroencephalographic signal over a fixed threshold; generating a zero-crossing representation of at least a segment of the obtained electroencephalographic signal with the identified zero-crossings; obtaining (D) a reference family of real functions of time and channels from a zero-crossing statistical analysis of zero-crossing representation of pre-recorded electroencephalographic signals; calculating (E) a matching score by comparing the zero-crossing representation of a segment of the electroencephalographic signal with at least one reference function from the reference family of functions; and computing the matching score as a function of time by sliding the at least one reference function from
    Type: Application
    Filed: March 30, 2018
    Publication date: April 1, 2021
    Applicants: BIOSERENITY, ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), SORBONNE UNIVERSITE
    Inventors: Jan PYRZOWSKI, Michel LE VAN QUYEN, Jean-Eudes LE DOUGET
  • Patent number: 10960015
    Abstract: Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 30, 2021
    Assignee: Assistance Publique-Hopitaux De Paris
    Inventors: Stéphane Auvin, Thomas Storme, Pascal Vaconsin, Vincent Boudy
  • Publication number: 20210085236
    Abstract: A system for calculating an indicator associated to a brain activity of a subject, the system including an acquisition module configured to acquire at least an epoch of electroencephalographic signal of a subject from a plurality of electrodes and a data processing module configured to carry out the steps of: calculating an average vector (VA) using as input of an autoencoder neural network (aNN) an electroencephalographic signals (ES) of a subject acquired from a plurality of electrodes; detecting (DET) the presence of at least a predefined pattern in the consecutive average values of the average vector (VA); and generating an indicator of brain activity (Idx) of the subject when detecting the predefined pattern.
    Type: Application
    Filed: December 21, 2018
    Publication date: March 25, 2021
    Applicants: BIOSERENITY, ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÈPINIÈRE), APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Mohcine HEDDI, Michel LE VAN QUYEN, Jean-Eudes LE DOUGET
  • Publication number: 20210088483
    Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the m
    Type: Application
    Filed: February 21, 2019
    Publication date: March 25, 2021
    Applicants: Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite De Paris, Ecole Nationale Superieure de Chimie de Paris
    Inventors: Hugo Salmon, Rabah Gahoual, Nathalie Mignet, Pascal Houze
  • Patent number: 10948498
    Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lorraine
    Inventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
  • Patent number: 10947598
    Abstract: Provided is an in vitro method for determining the metabolic status of a lymphoma comprising a step of determining the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells, wherein a low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. Also provided is an in vitro method for predicting the responsiveness of a patient afflicted with a lymphoma to a treatment with a metabolic inhibitor selected from the group consisting of mitochondrial metabolic inhibitors and glutamine metabolism inhibitors comprising a step of determining the level of GAPDH expression in lymphoma cells obtained from said patient, wherein a low level of GAPDH expression is predictive of a response to a treatment with a metabolic inhibitor.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: March 16, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Université Côte d'Azur, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jean-Ehrland Ricci, Johanna Chiche, Catherine Thieblemont
  • Patent number: 10941448
    Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 9, 2021
    Assignees: The Universite Paris-Saclay, The Assistance Publique-Hopitaux de Paris (APHP), The Institut National de la Sante et de la Recherche Medicale (INSERM), PML Screening, LLC
    Inventors: Eli Hatchwell, Peggy S. Eis, Edward B. Smith, III, Yassine Taoufik
  • Publication number: 20210052547
    Abstract: The present invention relates to a compound of formula (I): wherein: -n is 1 or 2; Z1, Z2 and Z3, identical or different, are selected from a hydrogen atom, a halogen atom and a (C1-C6)alkyl group; and —R is an optionally substituted (C1-C6)alkyl group by one or more substituents chosen from a hydroxyl, an oxo and a thiol group; or one of its pharmaceutically acceptable salts; for use to decrease urinary oxalate concentration in an individual. The present invention further relates to a compound of formula (I) for use in the prevention and/or treatment of diseases and/or conditions related to a high urinary oxalate concentration in an individual.
    Type: Application
    Filed: February 14, 2017
    Publication date: February 25, 2021
    Applicants: Institut National de la Sante et de la Recherche Medicale (NSERM), Assistance Publique-Hopitaux de Paris, Sorbonne Universite
    Inventors: Emmanuel Letavernier, Michel Daudon
  • Publication number: 20210040563
    Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 11, 2021
    Applicants: SORBONNE UNIVERSITE, CTRE RECHERCHE PATHOLOGIES PROSTATIQUES, LIGUE NATIONALE CONTRE LE CANCER, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE TOURS, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS
    Inventors: Olivier CUSSENOT, Aurélie KAMOUN, Aurélien DE REYNIES, Géraldine CANCEL-TASSIN, Gaëlle FROMONT-HANKARD
  • Publication number: 20210041457
    Abstract: The invention relates to a non-invasive process for evaluating the quality of one or more dense connective tissue(s) in a patient, comprising the following steps: a) Analyzing the profile of the microrelief of a cutaneous replica of a portion of the skin of said patient by at least one of the following step: a1. visually assessing on picture(s) of said cutaneous replica the line shape and the anisotropy of the lines; and/or a2. Determining, on picture(s) of said cutaneous replica, the roughness index of the microrelief with an optical sensor, b) identifying cutaneous replica of “stage 1”, representative of healthy skins, and cutaneous replica of “stage 2” representative of altered skins, a cutaneous replica of stage 2 being indicative of low quality of the one or more dense connective tissue(s) in the patients body.
    Type: Application
    Filed: September 24, 2018
    Publication date: February 11, 2021
    Applicants: ECOLE CENTRALE DE LYON, UNIVERSITE PARIS-SACLAY, UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Thierry HOC, Jean-Charles AUREGAN, Morad BENSIDHOUM, Catherine BOSSER, Hassan ZAHOUANI
  • Publication number: 20210038691
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 11, 2021
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
  • Publication number: 20210030703
    Abstract: In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 4, 2021
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE PARIS, SORBONNE UNIVERSITÉ, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS-SACLAY
    Inventors: Guido KROEMER, Sarah LEVESQUE, Jonathan POL
  • Publication number: 20210022638
    Abstract: This method for generating an indicator of the state of a patient in coma includes: generating at least one auditory stimulation by generating a sequence of auditory stimuli, the sequence producing evoked potentials in the patient; acquiring a first electroencephalographic signal produced by patient from at least one electrode; estimating at least one pair of values corresponding to a first parameter and a second parameter extracted from the first acquired signal, including estimating a first pair of values such that calculating the first parameter includes an estimation of the amplitude variance of the first signal within a predefined time window and the calculation of the second parameter includes an estimation of the correlation of two segments of the first signal; generating a state indicator for the or each pair of values of the first and second parameters, the values defining coordinates of a point in a reference base.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 28, 2021
    Applicants: PARIS SCIENCES ET LETTRES - QUARTIER LATIN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, ÉCOLE NORMALE SUPÉRIEURE, UNIVERSITÉ DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: David HOLCMAN, Adrien DOUMERGUE, Nathalie KUBIS, Alexandra RICHARD, Aymeric FLOYRAC
  • Patent number: 10874637
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration in with brain iron accumulation (NBIA). Studying two novel genes, namely, CRAT encoding the carnitine acetyltransferase and REPS1 involved in endocytosis and vesicle transport, and a series of known NBIA genes, the inventors reported on iron overload related to increased levels and abnormal recycling of transferrin receptor as a common feature in NBIA. They ascribe this anomaly, at least in part, to impaired palmitoylation of the receptor as a common consequence of the various disease causing mutations. Finally, the inventors show that Artesunate improved TfR1 palmitoylation in NBIA fibroblasts. In particular, the present invention relates to a method of treating neurodegeneration with brain iron accumulation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a drug increasing TfR1 palmitoylation.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: December 29, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DESCARTES, FONDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Anne Agnès Rötig, Anthony Drecourt
  • Publication number: 20200390817
    Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.
    Type: Application
    Filed: September 2, 2020
    Publication date: December 17, 2020
    Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université de Paris, Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Isabelle André, Marina Cavazzana, Kuiying Ma, John Tchen
  • Publication number: 20200383973
    Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.
    Type: Application
    Filed: July 21, 2020
    Publication date: December 10, 2020
    Applicants: Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite
    Inventors: Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin